Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 93 of 116 for:    Atenolol

Losartan/Amlodipine on Hemodynamics Parameters and Arterial Stiffness in Arterial Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03626259
Recruitment Status : Recruiting
First Posted : August 10, 2018
Last Update Posted : August 17, 2018
Sponsor:
Information provided by (Responsible Party):
Fernando Grover Paez, Centro Universitario de Ciencias de la Salud, Mexico

Brief Summary:
Systemic Arterial Hypertension (SAH) is a disease with a high prevalence in Mexico and worldwide. SAH is associated with an increase in cardiovascular morbidity and mortality, causing cardiovascular disease (CVD), heart failure (HF), as well as chronic kidney disease (CKD). Several of the physiopathological mechanisms observed are: the increase in cardiac output, central aortic pressure (CAP), pulse wave velocity (PWV) and peripheral vascular resistance (PVR), which leads to the generation of damage to the target organ. The identification not only of the peripheral arterial pressure, but also of these hemodynamic parameters and arterial stiffness would allow a better cardiovascular characterization of the patients. However, the measurements of hemodynamic parameters and arterial stiffness can vary during the 24 hours from individual to individual by all known mechanisms involved in the regulation of blood pressure such as cortisol, central nervous system, the peripheral nervous system, along with the renin angiotensin and aldosterone system, which are usually only measured in a single moment. Generally, the choice of drug in a patient with SAH is based only on the values of peripheral blood pressure at the time of the measurement. The use of oscillometric equipment such as the Mobil-O-Graph 24 allows to the investigators to know the hemodynamic and arterial stiffness behavior during 24 hours; therefore, this could favor the choice of the most appropriate antihypertensive drug, dose and administration time. The use of angiotensin II receptor antagonists (ARA II) At1 blockers such as losartan and calcium channel blockers (CCB) for instance amlodipine have shown a reduction in CAP and peripheral blood pressure respectively in patients with SAH. The most prescribed drugs in health units worldwide are enalapril, amlodipine, losartan and atenolol, of which the most used combination is losartan with amlodipine. There are no studies to date that allow investigators to identify the effect of the administration of losartan / amlodipine in a fixed combination form on the hemodynamic parameters and arterial stiffness of patients with SAH. Therefore, the objective of the present study is to evaluate the effect of this fixed combination versus losartan on hemodynamic and arterial stiffness parameters based on the behavior of these for 24 hours.

Condition or disease Intervention/treatment Phase
Hypertension Drug: Losartan and Amlodipine Drug: Losartan Phase 4

Detailed Description:
In the present investigation the investigators expect to know the effect of the administration of losartan / amlodipine in fixed combination versus losartan on hemodynamic parameters and arterial stiffness in patients with arterial hypertension grade 1 and 2. For this purpose the investigators will conduct a double-blind randomized trial, each group will be compose by 14 male and female patients, 40-65 years old, with hypertension, neither with diabetes nor being under triple pharmacological therapy. Randomization will determine who will receive the intervention during an 8- week trial (losartan/amlodipine in fixed combination capsule, 100mg/5mg 1 time daily or losartan capsule 100mg 1 time daily). The clinical findings and laboratory tests include a metabolic profile and biosafety, which will be at baseline and by the 8th week . Body weight, body fat, body mass index (BMI) and blood pressure will be determined during the initial and final visit, in addition to hemodynamics parameters of arterial stiffness like cardiac output, central aortic pressure (CAP), pulse wave velocity (PWV) and peripheral vascular resistance (PVR) by an oscillometric monitoring system via Mobil-O -Graph® 24. Adverse events and adherence to treatment will be documented. Statistical analysis: Mann-Whitney U Test and Wilcoxon exact test. It is considered with significance at p<0.05.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: assignment
Masking: Double (Participant, Investigator)
Masking Description: double blind (subject, investigator)
Primary Purpose: Treatment
Official Title: Effect of the Administration of Losartan / Amlodipine in Fixed Combination Versus Losartan on Hemodynamic and Arterial Stiffness Parameters in Patients With Systemic Hypertension Grade 1 and 2
Actual Study Start Date : August 6, 2018
Estimated Primary Completion Date : January 15, 2019
Estimated Study Completion Date : June 14, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
losartan and amlodipine
Individuals with SAH grade 1 or 2 without triple pharmacological therapy.
Drug: Losartan and Amlodipine
Losartan and amlodipine in fixed combination capsules, 100mg/5mg. One time daily with the first bite of eat meal per 8 weeks
Other Name: Bicartial

Active Comparator: Losartan
Individuals with SAH grade 1 or 2 without triple pharmacological therapy.
Drug: Losartan
Losartan capsules, 100mg. One time daily with the first bite of eat meal per 8 weeks




Primary Outcome Measures :
  1. Pulse Wave Velocity (PWVao) [ Time Frame: 56 days ]
    Before and after intervention with oscillometric monitoring system via Mobil-O -Graph® 24. Maximum score 12 m/s


Secondary Outcome Measures :
  1. Peripheral vascular resistance [ Time Frame: 56 days ]
    Before and after intervention with oscillometric monitoring system via via Mobil-O -Graph®. Maximum score 1.8s*mmHg/ml

  2. Cardiac output [ Time Frame: 56 days ]
    Before and after intervention with oscillometric monitoring system via via Mobil-O -Graph®. Maximum score 6.5L/min

  3. Pulse Pressure (PP) [ Time Frame: 56 days ]
    Before and after intervention with oscillometric monitoring system via via Mobil-O -Graph® 24. Maximun score <75 mmHg

  4. Augmentation Index (AIx) [ Time Frame: 56 days ]
    Before and after intervention with oscillometric monitoring system via via Mobil-O -Graph® 24. Maximum score 110%

  5. Systolic blood pressure [ Time Frame: 56 days ]
    Before and after intervention using a digital manometer. Maximum score 160 mmHg

  6. Diastolic blood pressure [ Time Frame: 56 days ]
    Before and after intervention using a digital manometer. Maximum score 100 mmHg

  7. Creatinine [ Time Frame: 56 days ]
    Before and after intervention by spectrophotometry. Maximum score 1.3 mg/dl



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of hypertension grade 1 or 2 according to the criteria of the American Heart Association (2017)
  • Written informed consent
  • Patients who are undergoing antihypertensive treatment and who, at the trial of the investigator and taking care of the health and safety of the patient, can undergo at least 2 weeks of washing prior to the visit of day 0 (it will be evaluated on a case-by-case basis).

Exclusion Criteria:

  • Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥120 mmHg
  • Diabetes Mellitus
  • Treated with triple pharmacological therapy
  • Untreated thyroid disease
  • Total cholesterol >400mg/dl
  • Triglycerides >400mg/dl
  • Liver enzymes (alt and ast) more tan twice the normal range
  • Glomerular filtration rate <60ml/min (Cockcroft-Gault)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03626259


Contacts
Layout table for location contacts
Contact: Fernando Grover Paez, PhD 3310585200 ext 33642 fgroverp@hotmail.com
Contact: Fernando Grover Paez, PhD 3310585200 ext 33642 fgroverpaez@hotmail.com

Locations
Layout table for location information
Mexico
Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara Recruiting
Guadalajara, Jalisco, Mexico, 44340
Contact: Fernando Grover Paez, PhD    3310585200 ext 33642    fgroverp@hotmail.com   
Sponsors and Collaborators
Centro Universitario de Ciencias de la Salud, Mexico
Investigators
Layout table for investigator information
Principal Investigator: Fernando Grover Paez, PhD Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara

Layout table for additonal information
Responsible Party: Fernando Grover Paez, Principal Investigator, Centro Universitario de Ciencias de la Salud, Mexico
ClinicalTrials.gov Identifier: NCT03626259     History of Changes
Other Study ID Numbers: CUCS-INTEC-MV-LOAM-001
First Posted: August 10, 2018    Key Record Dates
Last Update Posted: August 17, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Fernando Grover Paez, Centro Universitario de Ciencias de la Salud, Mexico:
hypertension
losartan/amlodipine
arterial stiffness
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases
Losartan
Amlodipine
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents
Anti-Arrhythmia Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists